Across the four trials, SGLT2 inhibitors reduced CVD death or hospitalization for HF in participants with diabetes (RR 0.74; 95% CI 0.66–0.82) but not in individuals without diabetes (RR 0.95; 95% CI 0.65–1.40). This evidence concerns the gene SLC5A2 and diabetes mellitus.